Figure 3.

326E treatment reduces hepatic de novo lipogenesis and VLDL-TGs secretion. (A) Schematic diagram of 326E treatment for hepatic de novo lipogenesis. Briefly, male C57BL/6J mice were fasted for 48 h followed by refeeding for another 48h. Animals then received 326E treatment at multi-dose followed by an intraperitoneally injection with 2 μCi [1,2-¹⁴C] acetate (in B, C) and 5 μCi [1,2-¹⁴C] acetate (in D, E) 1 h later dosing. One hour after [1,2-¹⁴C] acetate injection, the mice were sacrificed after anesthetization, and the hepatic lipogenesis was calculated; (B)–(C) The rate of ¹⁴C-labeled hepatic de novo lipogenesis after 326E (10, 30, 100 mg/kg) and BA (30 mg/kg) treatment (n = 5–6); (D)–(E) The rate of ¹⁴C-labeled de novo lipogenesis after 326E (30 mg/kg) in the liver, leg muscle, ileum, kidney, heart and abdominal fat (a-Fat) (n = 7–8); (F)–(I) Plasma TG (F) and TC (H) concentration under tyloxapol (600 mg/kg) injection were measured after 326E and BA treatment at the indicated dose (n = 10). The area under the curve of TG level (G) and TC (I) in 4 h of VLDL-TGs secretion were shown. Data are mean ± SEM; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to Veh. ^#P < 0.05, ^##P < 0.01, ^###P < 0.001 compared to indicated group. ns, not significant.